Source link : https://www.newshealth.biz/health-news/cognitive-decline-in-af-not-reduced-by-anticoagulation/
CHICAGO — A randomized placebo-controlled trial testing a direct oral anticoagulant for the prevention of cognitive decline in patients with atrial fibrillation (AF) has been halted early for futility. After a median follow-up of 3.7 years, there was no difference between rivaroxaban 15 mg and placebo for a composite primary endpoint that included cognitive decline, […]
Author : News Health
Publish date : 2024-12-02 07:21:41
Copyright for syndicated content belongs to the linked Source.